UGNE mit Powermeldung +50% bis jetzt - 500 Beiträge pro Seite

[morchel]

Klaxo Smith Kline will ein Haufen Geld abdrücken!

GlaxoSmithKline and Unigene Announce Agreement to Develop Oral Parathyroid Hormone for Osteoporosis
LONDON and FAIRFIELD, N.J., April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (GSK) and Unigene Laboratories, Inc. (OTC Bulletin Board: UGNE) today announce that they have completed a $150 million dollar licensing agreement to develop an oral formulation of an analog of parathyroid hormone (PTH) currently in advanced preclinical development for the treatment of osteoporosis.

Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop and commercialise the product. In return, GSK will make an up-front payment to Unigene and subsequent milestone payments. Total payments will amount to $150 million subject to the progress of the compound through clinical development and through to the market. In addition, GSK will underwrite all development activities during the program, including Unigene`s activities in the production of raw material for development and clinical supplies, and will pay Unigene a royalty on its worldwide sales of the product.

"We are pleased that Unigene has chosen GSK as its partner of choice", said Dr Allen Oliff, Senior Vice President of the Microbial, Musculoskeletal and Proliferative Diseases Centre for Excellence in Drug Discovery (CEDD) at GSK. "The addition of this oral formulation of parathyroid hormone to our development program in osteoporosis provides a mechanism that targets bone formation and thus complements our products in development that target bone resorption. There is a clear need for new treatment options, especially as osteoporosis becomes a growing healthcare issue in aging populations``.

At present, treatments for osteoporosis rely on anti-resorptive agents, which aim to reduce the "loss" of bone. Parathyroid hormone (PTH) is a naturally occurring hormone, a function of which is to increase plasma calcium levels. In trials, recombinant human PTH has been found to form new bone, and to reduce fracture. Agents which can induce bone formation are widely viewed as the next critical advance in the treatment of osteoporosis


und so weiter....

morchel

[Erwin2208]

Unigene`s U.S. NDA for FORTICAL-R-, Its Nasal Osteoporosis Product, Accepted for Review; $3 Million Milestone Achieved in Upsher-Smith Agreement

FAIRFIELD, N.J.--(BUSINESS WIRE)--May 5, 2003--Unigene Laboratories, Inc.`s (OTCBB:UGNE) New Drug Application ("NDA") for FORTICAL(R), its nasal calcitonin product for treating osteoporosis, has been accepted for review by the U. S. Food and Drug Administration ("FDA").

This event triggers a $3 million milestone payment from Upsher-Smith Laboratories, the Company`s exclusive U.S. licensing partner.

"We expect our current manufacturing operation for bulk calcitonin to meet the needs of Upsher-Smith in the U.S. as well as the anticipated demand for the nasal calcitonin product from prospective markets outside of the U.S.," commented Dr. Warren P. Levy, President and CEO of Unigene. "We are committed to being in position to support product launch as soon as approval is granted, and we are taking the necessary steps to accomplish this goal. Our considerable manufacturing experience with calcitonin and the valuable input and assistance we are receiving from Upsher-Smith will hopefully enable us to receive regulatory approval in a timely fashion."

[morchel]

morchel

[morchel]

up!

morchel

[morchel]

manchmal braucht man eben ein wenig geduld!

morchel